Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4079 - Frequency and clinical characteristics of breast cancer patients with high-risk features and no BRCA1/2 mutations in a Salentinian cohort


09 Oct 2016


Poster display


Elisabetta De Matteis


Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385


E. De Matteis1, M.R. De Giorgio1, P. Tarantino2, G. Ronzino1, M. Ciccarese1, L. Palma3, G. Surico1

Author affiliations

  • 1 Oncology, Ospedale Vito Fazzi, 73100 - Lecce/IT
  • 2 Genetics, Ospedale Vito Fazzi, 73100 - Lecce/IT
  • 3 Psychology, Ospedale Vito Fazzi, 73100 - Lecce/IT


Abstract 4079


The early onset of breast cancer (age 


Between 2014-2016 breast cancer patients and unaffected women with a familial history accessed to Hereditary and Familial Tumours Services at «Vito Fazzi» Hospital in Lecce and data were collected. Informed consents for genetic testing and research was obtained from all probands.


We analyzed a group of 29 breast cancer patients with high-risk features. In particular, 18 were EOBC and 11 were TNBC (4 of which both EOBC/TNBC). Of these 29 probands, 17 were BRCA WT and 12 were BRCA mutation carriers (10 BRCA1 and 2 BRCA2 mutations carriers). In this cohort of patients, we found no statistically significant differences between BRCA WT and BRCA carriers in terms of personal and clinical characteristics, including mean age at diagnosis, breast feeding, oral contraceptive use, parity; or in terms of pathological characteristics, including histological type, tumor size, grade, node involvement, HER2/NEU status. However, BRCA carriers more frequently presented a negative Estrogen receptor status.


To our knowledge, there are currently no studies that have described the clinical characteristics of breast cancer patients with high-risk features and no BRCA1/2 mutations in a Salentinian cohort. Furthermore, a considerable quota of these probands result BRCA1/2 WT. The long-term aim of the present analysis is to estimate, in a monoinstitutional cohort of patients, the frequency of BRCA WT breast patients with high-risk features eligible for further cancer susceptibility gene testing, and to describe their characteristics, in terms of clinical features, tumour subtypes, family risk profile and non-genetic/environmental risk factors.

Clinical trial identification

Legal entity responsible for the study

ASL Lecce


ASL Lecce


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings